Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

Innate immune recognition

Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) · Science · doi:10.1126/science.282.5396.2085 · Cited by 7,631

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

Bernard, G. R., Vincent, J., Laterre, P., LaRosa, S. P., Dhainaut, J.-F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441001 · Cited by 6,124

Toll-like receptors: critical proteins linking innate and acquired immunity

Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777

Toll-like receptors in the induction of the innate immune response

Aderem, A. A., & Ulevitch, R. J. (2000) · Nature · doi:10.1038/35021228 · Cited by 3,082

The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex

Park, B. S., Song, D. H., Kim, H. M., Choi, B., Lee, H., & Lee, J. (2009) · Nature · doi:10.1038/nature07830 · Cited by 2,513

Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin

Ziegler, E. J., Fisher, C. J., Sprung, C. L., Straube, R., SADOFF, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240701 · Cited by 1,618

Bacterial endotoxin: molecular relationships of structure to activity and function

Rietschel, E., Kirikae, T., Schade, F. U., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A. J., Zähringer, U., Seydel, U., Padova, F. D., et al. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.2.8119492 · Cited by 1,608

High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes

Andersson, U., Wang, H., Palmblad, K., Aveberger, A.-C., Bloom, O., Erlandsson-Harris, H., Janson, A., Kokkola, R., Zhang, M., Yang, H., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.565 · Cited by 1,401

Bacterial lipopolysaccharides and innate immunity

Alexander, C., & Rietschel, E. T. (2001) · Journal of Endotoxin Research · doi:10.1179/096805101101532675 · Cited by 1,206

Recognition of lipopolysaccharide pattern by TLR4 complexes

Park, B. S., & Lee, J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.97 · Cited by 1,276

The Gut Microbiome, Kidney Disease, and Targeted Interventions

Ramezani, A., & Raj, D. S. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013080905 · Cited by 773

TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis

Kuzmich, N. N., Сивак, К. В., Chubarev, V. N., Porozov, Y. B., Savateeva-Lyubimova, T. N., & Peri, F. (2017) · Vaccines · doi:10.3390/vaccines5040034 · Cited by 665

The gut microbiome and liver cancer: mechanisms and clinical translation

Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634

Toll-like receptors activation, signaling, and targeting: an overview

El-Zayat, S. R., Sibaii, H., & Mannaa, F. A. E. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0227-2 · Cited by 603

Modulating immunity as a therapy for bacterial infections

Hancock, R. E. W., Nijnik, A., & Philpott, D. J. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2745 · Cited by 558

Morphine activates neuroinflammation in a manner parallel to endotoxin

Wang, X., Loram, L. C., Ramos, K. M., de Jesus, A. J., Thomas, J., Cheng, K., Reddy, A., Somogyi, A. A., Hutchinson, M. R., Watkins, L. R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200130109 · Cited by 521

Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics

Gao, W., Xiong, Y., Li, Q., & Yang, H. Y. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00508 · Cited by 372

Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease

Caputi, V., & Giron, M. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061689 · Cited by 338

Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide

Lai, H., Lin, T., Chen, T.-W., Kuo, Y.-L., Chang, C., Wu, T.-R., Shu, C.-C., Tsai, Y.-H., Swift, S., & Lu, C. (2021) · Gut · doi:10.1136/gutjnl-2020-322599 · Cited by 341

Cytokine Storm—Definition, Causes, and Implications

Jarczak, D., & Nierhaus, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911740 · Cited by 336

Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective

Zhang, Y.-S., Liang, X., Bao, X., Xiao, W., & Chen, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114291 · Cited by 313

Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets

Kumar, V. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107087 · Cited by 285

Targeting Toll-Like Receptors: Promising Therapeutic Strategies for the Management of Sepsis-Associated Pathology and Infectious Diseases

Savva, A., & Roger, T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00387 · Cited by 271

TLR4 signalling in osteoarthritis—finding targets for candidate DMOADs

Gómez, R., Villalvilla, A., Largo, R., Gualillo, O., & Herrero‐Beaumont, G. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.209 · Cited by 230

Diagnosis and management for urosepsis

Wagenlehner, F., Lichtenstern, C., Rolfes, C., Mayer, K., Uhle, F., Weidner, W., & Weigand, M. A. (2013) · International Journal of Urology · doi:10.1111/iju.12200 · Cited by 225

Toll-like Receptor 4 (TLR4) Modulation by Synthetic and Natural Compounds: An Update

Peri, F., & Calabrese, V. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401006s · Cited by 187

Toll-Like Receptors in Liver Fibrosis: Cellular Crosstalk and Mechanisms

Yang, L., & Seki, E. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00138 · Cited by 184

Like Cures Like: Pharmacological Activity of Anti-Inflammatory Lipopolysaccharides From Gut Microbiome

Lin, T.-L., Shu, C.-C., Chen, Y.-M., Lu, J.-J., Wu, T.-S., Lai, W.-F., Tzeng, C.-M., Lai, H.-C., & Lu, C.-C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00554 · Cited by 143

New developments in Toll-like receptor targeted therapeutics

Connolly, D. J., & O'Neill, L. A. J. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.002 · Cited by 152

Discovery and Validation of a New Class of Small Molecule Toll-Like Receptor 4 (TLR4) Inhibitors

Neal, M. D., Jia, H., Eyer, B. R., Good, M. L., Guerriero, C. J., Sodhi, C. P., Afrazi, A., Prindle, T., Ma, C., Branca, M. F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065779 · Cited by 137

Extracellular histone release in response to traumatic injury

Kutcher, M., Xu, J., Vilardi, R. F., Ho, C., Esmon, C. T., & Cohen, M. J. M. (2012) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e318270d595 · Cited by 133

Toll-like receptor regulation of intestinal development and inflammation in the pathogenesis of necrotizing enterocolitis

Lü, P., Sodhi, C. P., & Hackam, D. J. (2013) · Pathophysiology · doi:10.1016/j.pathophys.2013.11.007 · Cited by 124

Targeting Toll-like receptors with small molecule agents

Wang, X., Smith, C., & Yin, H. H. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60039d · Cited by 117

The innate immune response to allotransplants: mechanisms and therapeutic potentials

Ochando, J., Ordikhani, F., Boros, P., & Jordan, S. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0216-2 · Cited by 108

The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death

Qiu, P., Cui, X., Barochia, A. V., Li, Y., Natanson, C., & Eichacker, P. Q. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.623125 · Cited by 94

Hypoxia Exacerbates Inflammatory Acute Lung Injury via the Toll-Like Receptor 4 Signaling Pathway

Wu, G., Xu, G., Chen, D., Gao, W., Xiong, J.-Q., Shen, H., & Gao, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01667 · Cited by 93

Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?

Brandão, S. C. S., Ramos, J. D. O. X., Dompieri, L. T., Godoi, E. T. A. M., de Figueiredo, J. L., SARINHO, E. S. C., Chelvanambi, S., & Aikawa, M. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.09.002 · Cited by 93

Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation

Tam, J. S. Y., Coller, J. K., Hughes, P. A., Prestidge, C. A., & Bowen, J. M. (2021) · Indian Journal of Gastroenterology · doi:10.1007/s12664-020-01114-y · Cited by 91

MD ‐2 as the target of a novel small molecule, L6H 21, in the attenuation of LPS ‐induced inflammatory response and sepsis

Wang, Y., Shan, X., Chen, G., Jiang, L., Wang, Z., Fang, Q., Liu, X., Wang, J., Zhang, Y., Wu, W., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13221 · Cited by 90

Computational Approaches to Toll-Like Receptor 4 Modulation

Billod, J., Lacetera, A., Guzman‐Caldentey, J., & Martín‐Santamaría, S. (2016) · Molecules · doi:10.3390/molecules21080994 · Cited by 88

Gut microbiota, hypertension and chronic kidney disease: Recent advances

Sircana, A., Michieli, F. D., Parente, R., Framarin, L., Leone, N., Berrutti, M., Paschetta, E., Bongiovanni, D., & Musso, G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.013 · Cited by 87

Size-dependent anti-inflammatory activity of a peptide-gold nanoparticle hybrid in vitro and in a mouse model of acute lung injury

Gao, W., Wang, Y., Xiong, Y., Sun, L., Wang, L., Wang, K., Lu, H. Y., Bao, A., Turvey, S. E., Li, Q., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.12.046 · Cited by 83

Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness

Barker, G., Leeuwenburgh, C., Brusko, T. M., Moldawer, L. L., Reddy, S. T., & Guirgis, F. W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081693 · Cited by 83

Lipopolysaccharide lipid A: A promising molecule for new immunity-based therapies and antibiotics

García-Vello, P., Lorenzo, F. D., Zucchetta, D., Zamyatina, A., Castro, C. D., & Molinaro, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107970 · Cited by 86

Toll-like Receptor 4 (TLR4) Antagonist Eritoran Tetrasodium Attenuates Liver Ischemia and Reperfusion Injury through Inhibition of High-Mobility Group Box Protein B1 (HMGB1) Signaling

McDonald, K.-A., Huang, H., Tohme, S. T., Loughran, P., Ferrero, K. M., Billiar, T. R., & Tsung, A. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00076 · Cited by 80

Anti-inflammation activity of exopolysaccharides produced by a medicinal fungus Cordyceps sinensis Cs-HK1 in cell and animal models

Li, L., Song, A.-X., Yin, J.-Y., Siu, K., Wong, W., & Wu, J. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.02.022 · Cited by 81

Post-screening characterisation and in vivo evaluation of an anti-inflammatory polysaccharide fraction from Eucommia ulmoides

Li, Q., Feng, Y., He, W., Wang, L., Wang, R., Dong, L., & Wang, C. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.04.034 · Cited by 78

Evidence of NI‐0101 pharmacological activity, an anti‐TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS

Monnet, E., Lapeyre, G., van Poelgeest, E. P., Jacqmin, P., de Graaf, K., Reijers, J. A. A., Moerland, M., Burggraaf, J., & de Min, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.522 · Cited by 79

Current insights in sepsis

Wiersinga, W. J. (2011) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32834a4aeb · Cited by 81

Curcumin Analog L48H37 Prevents Lipopolysaccharide-Induced TLR4 Signaling Pathway Activation and Sepsis via Targeting MD2

Wang, Y., Shan, X., Dai, Y., Jiang, L., Chen, G., Zhang, Y., Wang, Z., Dong, L., Wu, J., Guo, G., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.222570 · Cited by 77

An update on classification and management of urosepsis

Wagenlehner, F. R. A., Tandoğdu, Z., & Johansen, T. E. B. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000364 · Cited by 77

Rifampin inhibits Toll‐like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain

Wang, X., Grace, P. M., Pham, M. N., Cheng, K., Strand, K. A., Smith, C., Li, J., Watkins, L. R., & Yin, H. H. (2013) · The FASEB Journal · doi:10.1096/fj.12-222992 · Cited by 77

Natural Products with Toll-Like Receptor 4 Antagonist Activity

Molteni, M., Bosi, A., & Rossetti, C. (2018) · International Journal of Inflammation · doi:10.1155/2018/2859135 · Cited by 76

Discovery of 3-(Indol-5-yl)-indazole Derivatives as Novel Myeloid Differentiation Protein 2/Toll-like Receptor 4 Antagonists for Treatment of Acute Lung Injury

Liu, Z., Chen, L., Yu, P., Zhang, Y., Fang, B., Wu, C., Luo, W., Chen, X., Li, C., & Liang, G. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00316 · Cited by 72

The role of neutrophil extracellular traps in sepsis and sepsis-related acute lung injury

Zou, S., Jie, H., Han, X., & Wang, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110436 · Cited by 72

Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing

Kempf, T., Zarbock, A., Vestweber, D., & Wollert, K. C. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0847-y · Cited by 73

Identification of sepsis subtypes in critically ill adults using gene expression profiling

Maslove, D. M., Tang, B. M. P., & McLean, A. S. (2012) · Critical Care · doi:10.1186/cc11667 · Cited by 71

New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis

Huttunen, R., & Aittoniemi, J. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.08.004 · Cited by 69

Myeloid differentiation 2 as a therapeutic target of inflammatory disorders

Park, S. H., Kim, N. D., Jung, J., Lee, C., Han, S., & Kim, Y. S. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.001 · Cited by 67

Recent progress in the discovery of myeloid differentiation 2 (MD2) modulators for inflammatory diseases

Chen, L., Fu, W., Zheng, L., Wang, Y., & Liang, G. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.015 · Cited by 65

Toll-like Receptor 4 in Acute Kidney Injury

Vallés, P. G., Lorenzo, A. F. G., García, R. D., Cacciamani, V. E., Benardón, M. E., & Costantino, V. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021415 · Cited by 68

The Central Role of the Inflammatory Response in Understanding the Heterogeneity of Sepsis-3

Ding, R., Meng, Y., & Ma, X. (2018) · BioMed Research International · doi:10.1155/2018/5086516 · Cited by 68

Insight into TLR4 receptor inhibitory activity via QSAR for the treatment of Mycoplasma pneumonia disease

Zhu, Z., Rahman, Z.-U., Aamir, M., Shah, S. Z. A., Hamid, S., Bilawal, A., Li, S., & Ishfaq, M. (2023) · RSC Advances · doi:10.1039/d2ra06178c · Cited by 63

Conformationally Constrained Lipid A Mimetics for Exploration of Structural Basis of TLR4/MD-2 Activation by Lipopolysaccharide

Artner, D., Oblak, A., Ittig, S., Gárate, J. A., Horvat, S., Arrieumerlou, C., Hofinger, A., Oostenbrink, C., Jerala, R., Kosma, P., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4003199 · Cited by 62

Pattern recognition receptors as potential drug targets in inflammatory disorders

McKernan, D. P. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.09.001 · Cited by 65

Biology and Metabolism of Sepsis: Innate Immunity, Bioenergetics, and Autophagy

Lewis, A., Billiar, T. R., & Rosengart, M. R. (2016) · Surgical Infections · doi:10.1089/sur.2015.262 · Cited by 63

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments

Liu, Z., Yang, M., Yu, K., Lian, Z., & Deng, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989664 · Cited by 58

The molecular mechanism of species-specific recognition of lipopolysaccharides by the MD-2/TLR4 receptor complex

Oblak, A., & Jerala, R. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.034 · Cited by 55

Progress in the synthesis and biological evaluation of lipid A and its derivatives

Gao, J., & Guo, Z. (2017) · Medicinal Research Reviews · doi:10.1002/med.21447 · Cited by 50

Epigallocatechin-3-gallate inhibits TLR4 signaling through the 67-kDa laminin receptor and effectively alleviates acute lung injury induced by H9N2 swine influenza virus

Xu, M.-J., Liu, B.-J., Wang, C.-L., Wang, G., Tian, Y., Wang, S., Jun, L., Li, P.-Y., Zhang, R., Dong, W., et al. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.08.023 · Cited by 50

Discovery of caffeic acid phenethyl ester derivatives as novel myeloid differentiation protein 2 inhibitors for treatment of acute lung injury

Chen, L., Jin, Y., Chen, H., Sun, C., Fu, W., Zheng, L., Lu, M., Chen, P., Chen, G., Zhang, Y., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.066 · Cited by 48

Peptide–Gold Nanoparticle Hybrids as Promising Anti‐Inflammatory Nanotherapeutics for Acute Lung Injury: In Vivo Efficacy, Biodistribution, and Clearance

Xiong, Y., Gao, W., Xia, F., Sun, Y., Sun, L., Wang, X., Ben, S., Turvey, S. E., Yang, H. Y., & Li, Q. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800510 · Cited by 48

Novel toll-like receptor 4 (TLR4) antagonists identified by structure- and ligand-based virtual screening

Švajger, U., Brus, B., Turk, S., Sova, M., Hodnik, V., Anderluh, G., & Gobec, S. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.10.019 · Cited by 46

Inhibition of TLR4 signalling to dampen joint inflammation in osteoarthritis

Bartels, Y. L., van Lent, P. L. E. M., van der Kraan, P. M., Blom, A. B., Bonger, K. M., & van den Bosch, M. H. J. (2023) · Lara D. Veeken · doi:10.1093/rheumatology/kead493 · Cited by 46

Drugs to cure avian influenza infection – multiple ways to prevent cell death

Yuan, S. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.367 · Cited by 46

Investigation of the Anti-Inflammatory Activity of Fusaproliferin Analogues Guided by Transcriptome Analysis

Kuang, Q.-X., Lei, L.-R., Li, Q., Peng, W., Wang, Y., Dai, Y., Wang, D., Gu, Y., Deng, Y., & Guo, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881182 · Cited by 44

Nanocarriers for effective delivery: modulation of innate immunity for the management of infections and the associated complications

Ko, C., Zang, S., Zhou, Y., Zhong, Z., & Yang, C. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01582-8 · Cited by 46

A Key Role for the Endothelium in NOD1 Mediated Vascular Inflammation: Comparison to TLR4 Responses

Gatheral, T. L., Reed, D. M., Moreno, L., Gough, P. J., Votta, B. J., Sehon, C. A., Rickard, D. J., Bertin, J., Lim, E. K. S., Nicholson, A. G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042386 · Cited by 44

Sepsis Pathophysiology and Anesthetic Consideration

Yuki, K., & Murakami, N. (2015) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x15666150108114810 · Cited by 44

Toll-Like Receptor 4 Mediates Endothelial Cell Activation Through NF-κB but Is Not Associated with Endothelial Dysfunction in Patients with Rheumatoid Arthritis

Menghini, R., Campia, U., Tesauro, M., Marino, A., Rovella, V., Rodia, G., Schinzari, F., Tolusso, B., Daniele, N. D., Federici, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099053 · Cited by 42

Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation

Yahaya, M. A. F., Bakar, A. R. A., Stanslas, J., Nordin, N. N. M., Zainol, M., & Mehat, M. Z. (2021) · BMC Biotechnology · doi:10.1186/s12896-021-00697-4 · Cited by 40

Nano-engineered nerolidol loaded lipid carrier delivery system attenuates cyclophosphamide neurotoxicity – Probable role of NLRP3 inflammasome and caspase-1

Iqubal, A., Syed, M. A., Najmi, A. K., Azam, F., Barreto, G. E., Iqubal, M. K., Ali, J., & Haque, S. E. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113464 · Cited by 38

Unraveling immunosenescence in sepsis: from cellular mechanisms to therapeutics

Wang, Y., Zhang, H., & Miao, C. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07714-w · Cited by 41

Molecular simplification of lipid A structure: TLR4-modulating cationic and anionic amphiphiles

Calabrese, V., Cighetti, R., & Peri, F. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.05.011 · Cited by 37

Bolstering Immunity through Pattern Recognition Receptors: A Unique Approach to Control Tuberculosis

Pahari, S., Kaur, G., Aqdas, M., Negi, S., Chatterjee, D., Bashir, H., Singh, S., & Agrewala, J. N. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00906 · Cited by 37

microRNA‐30a inhibits the liver cell proliferation and promotes cell apoptosis through the JAK/STAT signaling pathway by targeting SOCS‐1 in rats with sepsis

Yuan, F., Chen, Y., Zhao, Y., Liu, Z., Nan, C., Zheng, B., Liu, X., & Chen, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28410 · Cited by 37

Balancing Innate Immunity and Inflammatory State via Modulation of Neutrophil Function: A Novel Strategy to Fight Sepsis

Fang, H., Jiang, W., Jin, C. S., Lu, Y., Liu, A., Kan, L., & Dahmen, U. (2015) · Journal of Immunology Research · doi:10.1155/2015/187048 · Cited by 36

Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses

Tamada, K., Nakajima, S., Ogawa, N., Inada, M., Shibasaki, H., Sato, A., Takasawa, R., Yoshimori, A., Suzuki, Y., Watanabe, N., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.136 · Cited by 36

Untangling Local Pro-Inflammatory, Reparative, and Regulatory Damage-Associated Molecular-Patterns (DAMPs) Pathways to Improve Transplant Outcomes

Dwyer, G. K., & Turnquist, H. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611910 · Cited by 35

Vizantin Inhibits Endotoxin-Mediated Immune Responses via the TLR 4/MD-2 Complex

Oda, M., Yamamoto, H., Shibutani, M., Nakano, M., Yabiku, K., Tarui, T., Kameyama, N., Shirakawa, D., Obayashi, S., Watanabe, N., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401796 · Cited by 32

A Purified Capsular Polysaccharide Markedly Inhibits Inflammatory Response during Endotoxic Shock

Piccioni, M., Monari, C., Kenno, S., Pericolini, E., Gabrielli, E., Pietrella, D., Perito, S., Bistoni, F., Kozel, T. R., & Vecchiarelli, A. (2012) · Infection and Immunity · doi:10.1128/iai.00553-12 · Cited by 31

Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma

Korff, S., Loughran, P., Cai, C., Lee, Y. S., Scott, M. J., & Billiar, T. R. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.03.023 · Cited by 30

Stem Cell-Induced Inflammation in Cholesteatoma Is Inhibited by the TLR4 Antagonist LPS-RS

Schürmann, M., Greiner, J. F. W., Volland-Thurn, V., Oppel, F., Kaltschmidt, C., Sudhoff, H. H., & Kaltschmidt, B. (2020) · Cells · doi:10.3390/cells9010199 · Cited by 29

Identification and analysis of novel endometriosis biomarkers via integrative bioinformatics

Bae, S., Jo, Y., Cho, M. K., Jin, J.-S., Kim, J., Shim, J., Kim, Y. H., Park, J.-K., Ryu, D., Lee, H. J., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.942368 · Cited by 28

Immunomodulatory approaches for prevention and treatment of infectious diseases

Nijnik, A. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.011 · Cited by 28

Exploring the Binding Proteins of Glycolipids with Bifunctional Chemical Probes

Liu, X., Dong, T., Zhou, Y., Huang, N., & Lei, X. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608827 · Cited by 28

Exogenous oxidants activate nuclear factor kappa B through Toll-like receptor 4 stimulation to maintain inflammatory phenotype in macrophage

Zhang, Y., & Igwe, O. J. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.11.012 · Cited by 26

Acute kidney injury: a conspiracy of toll-like receptor 4 on endothelia, leukocytes, and tubules

Lu, C. Y., Winterberg, P. D., Chen, J., & Hartono, J. R. (2011) · Pediatric Nephrology · doi:10.1007/s00467-011-2029-0 · Cited by 26

Computational approach to suggest a new multi-target-directed ligand as a potential medication for Alzheimer’s disease

Eslami, M., Nezafat, N., Negahdaripour, M., & Ghasemi, Y. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1564701 · Cited by 27

Effect of acute TLR4 inhibition on insulin resistance in humans

Liang, H., Sathavarodom, N., Colmenares, C., Gelfond, J., Espinoza, S. E., Ganapathy, V., & Musi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162291 · Cited by 28

Zhankuic Acid A Isolated from Taiwanofungus camphoratus Is a Novel Selective TLR4/MD-2 Antagonist with Anti-Inflammatory Properties

Chen, Y., Shiau, A., Wang, S., Yang, J., Chang, S.-J., Wu, C., & Wu, T.-S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301931 · Cited by 24

Key residues in TLR4-MD2 tetramer formation identified by free energy simulations

Tafazzol, A., & Duan, Y. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007228 · Cited by 25

The balance between proinflammatory, “bad”, and immunomodulatory, “good”, lipopolysaccharide for understanding gut-derived systemic inflammation

Tume, R., Sherbiny, S. E., Bono, R., Gautier, T., de Barros, J.-P. P., & Meroño, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1588129 · Cited by 26

Evolving Paradigms in Sepsis Management: A Narrative Review

Kim, M., Choi, E.-J., & Choi, E.-J. (2024) · Cells · doi:10.3390/cells13141172 · Cited by 24

Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma

Fatima, N., Akhtar, T., & Sheikh, N. (2017) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2017/6238106 · Cited by 22

Sepsis: the evolution of molecular pathogenesis concepts and clinical management

Feng, Z., Wang, L., Yang, J. L., Li, T., Liao, X., Kang, Y. M., Xiao, F., & Zhang, W. (2025) · MedComm · doi:10.1002/mco2.70109 · Cited by 23

Toll-Like Receptor 4 Plays a Central Role in Cardiac Dysfunction During Trauma Hemorrhage Shock

Zhang, X., Chen, L., Gao, M., Cao, X.-Y., Ha, T., Kalbfleisch, J. H., Williams, D. L., Li, C., & Kao, R. L. (2014) · Shock · doi:10.1097/shk.0000000000000155 · Cited by 20

Dose-Dependent Effects of Lipopolysaccharide on the Endothelium—Sepsis versus Metabolic Endotoxemia-Induced Cellular Senescence

Merk, D., Cox, F. F., Jakobs, P., Prömel, S., Altschmied, J., & Haendeler, J. (2024) · Antioxidants · doi:10.3390/antiox13040443 · Cited by 21

Novel Synthetic Toll-Like Receptor 4/MD2 Ligands Attenuate Sterile Inflammation

Hayashi, T., Crain, B., Yao, S., Caneda, C. D., Cottam, H. B., Chan, M., Corr, M., & Carson, D. A. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214312 · Cited by 19

Safety, pharmacokinetics, and pharmacodynamics of 4-hour intravenous infusion of eritoran tetrasodium in healthy Japanese and Caucasian males

Okubo, Y., Aikawa, N., Lynn, M., Rossignol, D. P., Wong, Y., Schuck, E. L., Kitahara, Y., Nakano, T., Sivak, O., Wasan, K. M., et al. (2011) · Critical Care · doi:10.1186/cc9685 · Cited by 2

Clinical Application of Eritoran as Drug Candidate for Sepsis Treatment

Park, S. H., Lee, K., Lim, H. K., Han, S., & Kim, Y. S. (2011)

Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis*

Barochia, A. V., Cui, X., Natanson, C., & Eichacker, P. Q. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181b77fe3 · Cited by 12

Eritoran: the evidence of its therapeutic potential in sepsis

Raja, R. (2007) · Core evidence · doi:10.2147/ce.s7430 · Cited by 7

Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564), a TLR4 Antagonist, in Patients with Severe Sepsis.

Kalil, A. C., LaRosa, S. P., Gogate, J. P., Lynn, M., Wittek, A. E., & Opal, S. M. (2009) · doi:10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4696